Bilcare Ltd
Incorporated in 1987, Bilcare Ltd. is engaged in the business of Pharmaceutical Packaging, Global Clinical Services, R&D services and Anti Counterfeit Technology (nCid).
- Market Cap ₹ 130 Cr.
- Current Price ₹ 55.2
- High / Low ₹ 95.4 / 51.0
- Stock P/E
- Book Value ₹ 202
- Dividend Yield 0.00 %
- ROCE 0.82 %
- ROE -6.34 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.27 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -24.3% over past five years.
- Promoter holding is low: 30.0%
- Company has a low return on equity of -8.51% over last 3 years.
- Contingent liabilities of Rs.721 Cr.
- Working capital days have increased from 69.2 days to 115 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3,547 | 3,062 | 2,692 | 2,603 | 2,633 | 2,778 | 2,997 | 1,827 | 623 | 845 | 982 | 747 | 771 | |
3,159 | 2,819 | 2,506 | 2,396 | 2,443 | 2,617 | 2,827 | 1,782 | 572 | 784 | 925 | 708 | 735 | |
Operating Profit | 387 | 243 | 186 | 207 | 190 | 161 | 170 | 45 | 51 | 60 | 57 | 39 | 36 |
OPM % | 11% | 8% | 7% | 8% | 7% | 6% | 6% | 2% | 8% | 7% | 6% | 5% | 5% |
-8 | 24 | 9 | -87 | 107 | 297 | 59 | 254 | 45 | 44 | 237 | 16 | 10 | |
Interest | 167 | 217 | 236 | 151 | 176 | 249 | 283 | 174 | 76 | 69 | 60 | 82 | 88 |
Depreciation | 148 | 141 | 191 | 164 | 177 | 416 | 378 | 239 | 46 | 39 | 38 | 45 | 47 |
Profit before tax | 63 | -91 | -232 | -194 | -56 | -207 | -433 | -114 | -25 | -4 | 196 | -72 | -88 |
Tax % | 30% | 25% | -7% | -58% | 42% | -4% | 5% | -13% | -55% | 3% | 74% | -18% | |
44 | -114 | -216 | -82 | -80 | -199 | -453 | -99 | -11 | -4 | 50 | -59 | -78 | |
EPS in Rs | 16.81 | -48.14 | -91.76 | -36.04 | -35.91 | -85.43 | -193.28 | -43.97 | -8.95 | -5.35 | 6.39 | -14.12 | -17.06 |
Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% |
Compounded Sales Growth | |
---|---|
10 Years: | -13% |
5 Years: | -24% |
3 Years: | 6% |
TTM: | -9% |
Compounded Profit Growth | |
---|---|
10 Years: | 6% |
5 Years: | 14% |
3 Years: | 0% |
TTM: | -69% |
Stock Price CAGR | |
---|---|
10 Years: | 0% |
5 Years: | 21% |
3 Years: | -12% |
1 Year: | -23% |
Return on Equity | |
---|---|
10 Years: | -35% |
5 Years: | -40% |
3 Years: | -9% |
Last Year: | -6% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
Reserves | 1,302 | 1,300 | 1,073 | 689 | 590 | 376 | -93 | 85 | 63 | 52 | 507 | 474 | 452 |
2,104 | 2,146 | 2,311 | 2,122 | 2,014 | 2,089 | 2,270 | 707 | 677 | 690 | 639 | 756 | 739 | |
971 | 899 | 933 | 786 | 830 | 913 | 888 | 297 | 300 | 362 | 424 | 314 | 329 | |
Total Liabilities | 4,400 | 4,368 | 4,340 | 3,620 | 3,457 | 3,402 | 3,087 | 1,112 | 1,064 | 1,127 | 1,593 | 1,568 | 1,543 |
1,493 | 2,126 | 1,926 | 2,432 | 2,403 | 2,180 | 2,005 | 534 | 494 | 465 | 1,045 | 1,038 | 971 | |
CWIP | 846 | 262 | 218 | 161 | 149 | 170 | 79 | 0 | 0 | 1 | 1 | 1 | 1 |
Investments | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 8 | 12 |
2,061 | 1,979 | 2,196 | 1,026 | 904 | 1,051 | 1,003 | 577 | 570 | 661 | 545 | 521 | 559 | |
Total Assets | 4,400 | 4,368 | 4,340 | 3,620 | 3,457 | 3,402 | 3,087 | 1,112 | 1,064 | 1,127 | 1,593 | 1,568 | 1,543 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
227 | 314 | -315 | 177 | 300 | 98 | 206 | 256 | 72 | 41 | -7 | 62 | |
-966 | -351 | 247 | -358 | -129 | -203 | -104 | 1,309 | 2 | -4 | 36 | -106 | |
661 | 48 | 119 | 149 | -155 | 91 | -103 | -1,600 | -83 | -55 | -19 | 36 | |
Net Cash Flow | -78 | 12 | 50 | -32 | 16 | -13 | -1 | -35 | -9 | -18 | 10 | -7 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 106 | 105 | 125 | 35 | 29 | 38 | 38 | 22 | 90 | 95 | 70 | 73 |
Inventory Days | 80 | 103 | 105 | 108 | 84 | 90 | 82 | 28 | 90 | 83 | 42 | 77 |
Days Payable | 90 | 76 | 93 | 86 | 81 | 102 | 71 | 35 | 93 | 102 | 77 | 70 |
Cash Conversion Cycle | 95 | 132 | 137 | 57 | 32 | 25 | 49 | 15 | 88 | 76 | 34 | 80 |
Working Capital Days | 130 | 145 | 156 | 35 | 16 | 24 | 28 | 27 | 67 | 57 | 36 | 115 |
ROCE % | 8% | 3% | 1% | 2% | 2% | -8% | -6% | -9% | 3% | 3% | 3% | 1% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Nov - Newspaper Publication of Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended 30th September 2024
-
Unaudited Financial Results (Standalone And Consolidated) For The Quarter & Half Year Ended 30Th September 2024
13 Nov - Bilcare Limited approved unaudited financial results for Q2 2024.
-
Board Meeting Outcome for Board Meeting Outcome For Unaudited Financial Results (Standalone And Consolidated) For The Quarter & Half Year Ended 30Th September 2024 Together With The Limited Review Report Of The Statutory Auditor Thereon.
13 Nov - Bilcare Limited approved Q2 FY2024 financial results.
- Board Meeting Intimation for Considering And Approving The Un-Audited Financial Results For The Quarter And Half Year Ended September 30, 2024. 6 Nov
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
17 Oct - Certificate under Regulation 74(5) of SEBI submitted.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Products & Services offered:
a) Pharma Packaging:[1]
Pharma Packaging is available in two broad categories viz., Polymer based Packaging Films and Aluminum based Packaging Foils. Their sub-categories are:
Blister Films
Blister Foils
Lidding Foils
CR Foils
Laminates
b) Global Clinical Supplies and Services:[2]
Company handles domestic and global manufacturing of IMPs and Placebos, Primary
and secondary packaging with various blinding techniques, IWRS, Storage at variable temperatures.